Navigation Links
Hikma - 2007 Preliminary Results Interviews With CEO and CFO
Date:3/18/2008

LONDON, March 18 /PRNewswire-FirstCall/ -- In video interviews Said Darwazah, CEO, and Bassam Kanaan, CFO, discuss Hikma's 2007 performance, financing and acquisitions, plus what they are expecting from the company in 2008. The interviews, transcripts, podcasts and vodcasts are available now on http://www.cantos.com.

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives.

If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE Hikma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
4. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
8. Symmetry Medical Reports Preliminary Third Quarter Revenue
9. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
10. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
11. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... (PRWEB) , ... August 22, 2017 , ... Mettler-Toledo, one ... its V2630 vision inspection system . This turnkey system inspects labels, prints, and ... to the requirements of different production lines and extended as needed. , The ...
(Date:8/23/2017)... ... ... Having proven that its Disruptor™ technology is more than ... Cell Technologies® (GCT®), has turned its attention to the lucrative fruit sugar ... ushering in a new era of modern, cost effective and more natural processing ...
(Date:8/23/2017)... MN (PRWEB) , ... August 23, 2017 , ... ... by health systems and academic medical centers. The network provides members nationally scaled ... limited-distribution drugs and biologics and restrictive payer agreements so members can provide continuity ...
(Date:8/22/2017)... ... August 22, 2017 , ... KBioBox is pleased ... technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted their core technology and direct ... scientists with easy to understand reports, extended indel analysis, and translocation analysis. , ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):